arrow
P

Payam Nahid

university of california irvine
H指数:48
被引数:1.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

2026-08-140
PRE
Evaluating the Cepheid Xpert TB/LTBI Research-Use-Only Assay for Detection of Active and Latent Mycobacterium tuberculosis Infection

评估Cepheid Xpert TB/LTBI研究专用试剂盒在活动性和潜伏性结核分枝杆菌感染检测中的应用

2026-02-010
PRE
Diagnostic accuracy of swab-based molecular tests for tuberculosis using near-point-of-care platforms: a multi-country evaluation

基于拭子样本的分子检测方法在近床边平台上的结核病诊断准确性:一项多国评估

2025-10-310
OAAI
Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial

贝达喹啉、德拉马尼、利奈唑胺和氯法齐明用于利福平耐药和氟喹诺酮类耐药结核病(endTB-Q):一项开放标签、多中心、分层、非劣效性、随机对照、III期试验

2025-07-160
PREAI
Efficacy and Safety of 4-Month Rifapentine-Based Tuberculosis Treatments in Persons with Diabetes

4个月利福喷丁为基础的结核病治疗方案在糖尿病患者中的疗效与安全性

2025-03-010
OA
Diagnostic Accuracy of Tuberculosis Screening Tests in a Prospective Multinational Cohort: Chest Radiography With Computer-Aided Detection, Xpert Tuberculosis Host Response, and C-Reactive Protein

前瞻性跨国队列中结核病筛查测试的诊断准确性: 计算机辅助检测的胸部x线摄影,Xpert结核病宿主反应和C反应蛋白

2024-11-072
OA
Risk-stratified treatment for drug-susceptible pulmonary tuberculosis

药物敏感肺结核的风险分层治疗

2024-10-301
OA
Pharmacokinetic-Pharmacodynamic Evidence From a Phase 3 Trial to Support Flat-Dosing of Rifampicin for Tuberculosis
2024-03-110
OAAI
Transcriptional adaptation of Mycobacterium tuberculosis that survives prolonged multi-drug treatment in mice
MBIO
IF4.7
2023-12-193
OAAI
Scientific advances and the end of tuberculosis: a report from the Lancet Commission on Tuberculosis
LANCET
IF88.5
2023-10-0114
PRE